Brand Name
Brineura
Generic Name
Cerliponase
View Brand Information FDA approval date: April 27, 2017
Form: Kit
What is Brineura (Cerliponase)?
BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 , also known as tripeptidyl peptidase 1 deficiency. BRINEURA is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 , also known as tripeptidyl peptidase 1 deficiency.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment